echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Putting a "new weapon" on the oncolytic virus to treat pancreatic cancer shows a higher effect

    Putting a "new weapon" on the oncolytic virus to treat pancreatic cancer shows a higher effect

    • Last Update: 2021-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, TILT Biotherapeutics announced that the oncolytic virus TILT-452 expressing IL-2 variants developed using the company’s oncolytic virus immunotherapy platform has achieved positive results in preclinical experiments


    TILT-452 (named Ad5/3-E2F-d24-vIL2 in the paper) is an engineered 5/3 serotype chimeric adenovirus


    ▲The virus design structure of TILT-452 (picture source: reference [2])

    In the pancreatic cancer hamster model, the tumors in the animals treated with TILT-452 shrank significantly, and at the end of the experiment (160 days later), 62.


    ▲TILT-452 treatment significantly reduces tumor volume and prolongs animal survival time (blue line, image source: reference [2])

    TILT said that the company’s main oncolytic virus therapy TILT-123 built on TILT-452 is currently undergoing evaluation in phase 1 clinical trials


    ▲Design structure of TILT-123 oncolytic virus (picture source: TILT company official website)

    TILT entered into a clinical cooperation agreement with Merck & Co.


    Reference materials:

    [1] TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.